贫血对接受免疫治疗的晚期实体瘤患者预后的影响

Effect of anemia on prognosis of patients with advanced solid tumors receiving immunotherapy

目的探讨贫血对接受免疫治疗的晚期实体瘤患者预后的影响。方法59例晚期实体瘤患者,搜集患者的基本资料、免疫治疗前血红蛋白(Hb)浓度及生存情况,并分析患者无进展生存时间(PFS)的影响因素。结果单因素分析显示,功能状态评分(PS)、贫血情况是接受免疫治疗的晚期实体瘤患者PFS的影响因素(P<0.05);多因素分析显示,PS评分≥2分、中度贫血是接受免疫治疗的晚期实体瘤患者PFS的独立危险因素(P<0.05)。59例患者的中位PFS是6.7个月,Hb水平正常、轻度贫血患者的中位PFS分别为6.9、6.7个月,均明显长于中度贫血患者的1.9个月(P<0.05);轻度贫血患者与Hb水平正常患者的中位PFS比较无统计学差异(P>0.05)。结论在接受免疫治疗的晚期实体瘤患者中,合并贫血的患者中位PFS短于无贫血患者的中位PFS,是影响接受免疫治疗的晚期实体瘤患者预后的危险因素之一。

Objective To explore the effect of anemia on prognosis of patients with advanced solid tumors receiving immunotherapy.Methods Basic data,hemoglobin(Hb)concentration before immunotherapy and survival were collected in 59 patients with advanced solid tumors,and the influencing factors of progression-free survival(PFS)were analyzed.Results Univariate analysis showed that performance status(PS)score and anemia were the influencing factors of PFS in patients with advanced solid tumors receiving immunotherapy(P<0.05).Multivariate analysis showed that PS score≥2 points and moderate anemia were independent risk factors for PFS in patients with advanced solid tumors receiving immunotherapy(P<0.05).The median PFS of 59 patients was 6.7 months,and the median PFS of patients with normal Hb level and mild anemia were 6.9 months and 6.7 months,respectively,which were significantly longer than 1.9 months of patients with moderate anemia(P<0.05).There was no significant difference in median PFS between patients with mild anemia and patients with normal Hb levels(P>0.05).Conclusion In patients with advanced solid tumors receiving immunotherapy,the median PFS of patients with anemia is shorter than that of patients without anemia,which is one of the risk factors affecting the prognosis of patients with advanced solid tumors receiving immunotherapy.